Sign in

You're signed outSign in or to get full access.

John Neuman

Director at SeaStar Medical Holding
Board

About John Neuman

Independent director since 2024; age 59; CPA with an Accounting degree from Michigan State University. Retired in 2023 after 30 years at Dow, most recently Vice President of Global Financial Accounting overseeing >350 staff, SEC reporting across >400 legal entities, and major M&A integrations (Rohm & Haas, Dow Corning, DowDuPont). Former audit manager at Deloitte; member of MSU’s External Advisory Board for Accounting & Information Systems .

Past Roles

OrganizationRoleTenureCommittees/Impact
Dow Chemical CompanyVice President, Global Financial Accounting1993–2023Led global financial accounting, SEC filings, corporate controllers oversight; managed integration/reporting for Rohm & Haas, Dow Corning, DowDuPont transactions .
Deloitte & Touche LLPAudit ManagerPre-1993Public-company audit experience; foundational external reporting and controls background .

External Roles

OrganizationRoleTenureCommittees/Impact
Michigan State University, Dept. of Accounting & Information SystemsExternal Advisory Board MemberNot disclosedAdvisory role to department programs and curriculum .

Board Governance

  • Independence: Board determined Neuman is independent under Nasdaq standards; majority of the Board and all committee members are independent .
  • Committee assignments: Audit Committee Chair; Nominating & Corporate Governance Committee member; not on Compensation Committee .
  • Financial expert: Board designated Neuman as “audit committee financial expert” under Item 407(d)(5) of Regulation S‑K .
  • Attendance: Board held 13 meetings in 2024; except for two departing directors, all directors met at least 75% attendance (includes Neuman’s partial-year service) .
  • Board leadership & executive sessions: Independent Chair (Rick Barnett); non-management and independent directors meet in executive session regularly; Chair presides .

Fixed Compensation

Component2024 Amount (USD)Vesting / Terms
Cash director fees$30,000 Earned in 2024; the company disclosed fees were not paid during FY2024 due to cash constraints .
Stock awards (RSUs)$26,080 (grant-date fair value) RSUs vest 33.33% annually on June 30, 2025, 2026, 2027 .
Options$0 No option awards to non-employee directors in 2024 .
Total$56,080

Additional limits/policies:

  • Non-employee director annual cap: Total cash + equity awards to any non-employee director capped at $500,000 per calendar year (grant-date fair value basis) under 2022 Omnibus Plan .
  • Anti-hedging: Directors prohibited from hedging Company stock .
  • Clawback: Company adopted compensation recovery policy compliant with SEC/Nasdaq rules, focused on incentive-based pay after restatement; no recovery applied to 2021–2023 since no incentive pay tied to financial metrics was granted to executives in those years .

Performance Compensation

Performance MetricDisclosure
Director performance-linked pay (PSUs/TSR/EBITDA/etc.)None disclosed for directors; Neuman’s 2024 RSUs vest based on time (no performance conditions) .
Options/PSUs Repricing or modificationsNone disclosed for directors; Plan prohibits repricing of options/SARs without shareholder approval .

Other Directorships & Interlocks

CompanyRoleCommittee RolesNotes
None disclosedICU’s 2025 proxy does not disclose any other current public-company directorships for Neuman .

No related-party interlocks or supplier/customer board overlaps were disclosed involving Neuman. ICU maintains a related person transaction policy and the Audit Committee reviews such transactions; disclosures since Jan 1, 2023 do not identify transactions involving Neuman .

Expertise & Qualifications

  • CPA; deep technical accounting and SEC reporting expertise; designated audit committee financial expert .
  • Large-scale controllership leadership (>350 team members) and complex multi-entity consolidation experience .
  • M&A integration/reporting for major transactions (Rohm & Haas, Dow Corning, DowDuPont), relevant to control environment and disclosure quality .
  • Prior Big Four audit management experience (Deloitte) .

Equity Ownership

MetricApr 16, 2025Oct 27, 2025
Beneficial ownership (shares)40,000 82,667
Ownership % of outstanding<1% <1%

Notes:

  • Section 16 reporting: Company disclosed Neuman filed a Form 4 on Feb 27, 2025 covering four transactions on Jun 16, Jun 17, Aug 15, and Dec 11, 2024 .
  • Pledging/hedging: Hedging prohibited by policy; no pledging disclosures found for Neuman .

Insider Trades (Form 4 Timing)

Transaction DateFiling DateNotes
2024-06-162025-02-27Reported on single filing covering multiple transactions .
2024-06-172025-02-27
2024-08-152025-02-27
2024-12-112025-02-27

Governance Assessment

  • Strengths

    • Independent director; Audit Chair with “financial expert” designation; strong accounting/SEC pedigree improves oversight of controls and reporting .
    • Clear governance scaffolding: independent committees, executive sessions, anti-hedging, clawback adoption post-restatement .
    • Ownership alignment via RSUs; director award cap limits over-compensation risk .
  • Watch items / red flags

    • Section 16 timeliness: Neuman’s multi-transaction Form 4 was filed months after transactions; while disclosed, late filings can signal administrative control gaps to monitor .
    • Liquidity constraints: Company disclosed unpaid 2024 director fees due to cash constraints, which can pressure board independence and retention; highlight capital structure risk context (not attributable to Neuman individually) .
    • Ongoing capital actions and Nasdaq compliance efforts (reverse split/authorized shares changes) indicate financing dependence—Audit Chair should continue close oversight of going-concern disclosures and financing covenants .
  • Related-party/conflict review

    • No related-party transactions disclosed involving Neuman; Audit Committee (chaired by Neuman) reviews related party matters and conflicts under policy .
  • Overall

    • Neuman’s profile (CPA, Dow VP, SEC/M&A depth) is additive to board effectiveness, particularly as Audit Chair amid restatement history and financing complexity; continued focus on timeliness of insider reporting and cash compensation accruals is warranted .